首页> 美国卫生研究院文献>Nucleic Acids Research >Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
【2h】

Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

机译:肿瘤抑制因子p53对纤溶酶原激活剂和抑制剂基因转录的差异调节。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The ability of p53 to activate or repress transcription suggests that its biological function as tumor suppressor is in part accomplished by regulating a number of genes including such required for inhibition of cell growth. We here give evidence that p53 also may regulate genes responsible for the proteolytic degradation of the extracellular matrix, which is considered a crucial feature for local invasion and metastasis of neoplastic cells. An important and highly regulated cascade of such proteolytic events involves the plasminogen activator system. We show that wild-type p53 represses transcription from the enhancer and promoter of the human urokinase-type (u-PA) and the tissue-type plasminogen activator (t-PA) gene through a non-DNA binding mechanism. Oncogenic mutants lost the repressing activity. In contrast, wild-type but not mutant p53 specifically binds to and activates the promoter of the plasminogen activator inhibitor type-1 (PAI-1) gene. Interestingly, one of the p53 mutants (273his) inhibited PAI-1 promoter activity. Our results suggest that altered function of oncogenic forms of p53 may lead to altered expression of the plasminogen activators and their inhibitor(s) and thus to altered activation of the plasminogen/plasmin system during tumor progression.
机译:p53激活或抑制转录的能力表明,其作为肿瘤抑制因子的生物学功能部分是通过调节许多基因来实现的,包括抑制细胞生长所需的基因。我们在这里提供证据,p53也可能调控负责细胞外基质蛋白水解降解的基因,这被认为是肿瘤细胞局部侵袭和转移的关键特征。这种蛋白水解事件的重要且高度受调控的级联涉及纤溶酶原激活剂系统。我们显示野生型p53抑制人类尿激酶型(u-PA)和组织型纤溶酶原激活物(t-PA)基因的增强子和启动子通过非DNA结合机制的转录。致癌突变体失去了抑制活性。相反,野生型而非突变型p53特异性结合并激活纤溶酶原激活物抑制剂1型(PAI-1)基因的启动子。有趣的是,p53突变体(273his)之一抑制了PAI-1启动子的活性。我们的结果表明,p53致癌形式功能的改变可能导致纤溶酶原激活剂及其抑制剂的表达发生改变,从而导致肿瘤进展过程中纤溶酶原/纤溶酶系统的激活发生改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号